Form 4: Neogenomics General Counsel Alicia C. Olivo Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Alicia C. Olivo, General Counsel of Neogenomics, filed a Form 4 detailing changes in her beneficial ownership, including stock vesting and tax obligation fulfillment.
Summary
- On May 3, 2024, Alicia C. Olivo, General Counsel of Neogenomics Inc., filed a Form 4 with the SEC.
- The filing reports changes in her beneficial ownership of Neogenomics securities.
- These changes include the surrender of 652 shares to cover tax obligations related to the vesting of restricted stock on May 1, 2024.
- The filing also notes the acquisition of 282 shares through Neogenomics' Employee Stock Purchase Plan (ESPP).
- Ms. Olivo directly owns 34,496 shares of common stock following the reported transactions.
- The filing also details Ms. Olivo's holdings of various stock options, restricted stock units, and performance stock units with different vesting schedules and exercise prices.
Sentiment
Score: 6
Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It reflects routine transactions related to executive compensation.
Positives
- The reporting person continues to hold a significant number of shares and stock options in the company, indicating a continued alignment with the company's success.
Future Outlook
The document does not contain explicit forward-looking statements, but the vesting schedules of stock options, restricted stock units, and performance stock units suggest continued service and potential future equity ownership for the reporting person.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing is specific to Neogenomics and provides insight into the equity compensation and ownership structure of its executives.
Comparison to Industry Standards
- Equity compensation practices vary across the industry, but stock options and restricted stock units are common tools used to align management's interests with those of shareholders.
- Companies like Exact Sciences and Guardant Health also utilize similar equity compensation plans for their executives.
- The vesting schedules and performance criteria associated with these grants are tailored to the specific goals and objectives of Neogenomics.
Stakeholder Impact
- The filing provides transparency to shareholders regarding the equity ownership of a key executive.
- It also reflects the company's compensation practices and how they incentivize management.
Key Dates
| Date | Description |
|---|---|
| 09/30/2019 | Ms. Olivo was granted 1,394 stock options. |
| 05/01/2020 | Ms. Olivo was granted 1,024 stock options. |
| 05/01/2021 | Ms. Olivo was granted 516 stock options. |
| 08/01/2021 | Ms. Olivo was granted 1,117 stock options. |
| 05/01/2022 | Ms. Olivo was granted 22,222 stock options. |
| 09/01/2022 | Ms. Olivo was granted 55,332 stock options. |
| 05/11/2023 | Ms. Olivo was granted 36,508 stock options, 19,508 restricted stock units, and 19,508 performance stock units. |
| 05/01/2024 | Vesting of restricted stock; 652 shares surrendered for tax obligations. |
| 02/23/2024 | Ms. Olivo was granted 42,344 stock options, 25,329 restricted stock units, and 25,330 performance stock units. |
| 05/03/2024 | Date of Form 4 filing. |
| 05/11/2026 | Performance stock units granted on May 11, 2023, may vest. |
| 02/23/2027 | Performance stock units granted on February 23, 2024, may vest. |
| 09/30/2026 | Expiration date for some stock options. |
| 05/01/2027 | Expiration date for some stock options. |
| 05/01/2028 | Expiration date for some stock options. |
| 08/01/2028 | Expiration date for some stock options. |
| 05/01/2029 | Expiration date for some stock options. |
| 09/01/2029 | Expiration date for some stock options. |
| 05/11/2030 | Expiration date for some stock options. |
| 02/23/2034 | Expiration date for some stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.